Advertisement

Liver Cancer pp 387-406 | Cite as

Colorectal Liver Metastases: 18F-Fluorodeoxyglucose-Positron Emission Tomography

  • Stéphanie Truant
  • Damien Huglo
  • François-René Pruvot
Part of the Methods of Cancer Diagnosis, Therapy and Prognosis book series (HAYAT, volume 5)

During the last years, 18F-fluorodeoxyglucosepositron emission tomography (FDG-PET) has been advocated as a useful tool in the management of recurrent colorectal cancer, mainly in liver and pelvic recurrences, whereas regarding the primary tumor, FDG-PET has proven to show very poor yield in comparison with conventional diagnostic methods. In the first meta-analysis of the literature for whole-body FDG-PET detection of recurrent colorectal cancer, FDG-PET had a positive impact on surgical decision-making in 29% of patients (Huebner et al., 2000). On the other hand, in the beginning of FDG-PET, most studies on colorectal liver metastases have shown limitations. Survey of previous reports shows indeed heterogeneous study designs that were mostly retrospective and simultaneously included various subsets of circumstances, e.g., preopera-tive staging of liver metastases together with locoregional recurrence, unexplained elevated serum carcinoembryonic antigen (CEA) levels and/or symptoms with negative imaging. The methodology to define the true lesion status of the FDG-PET findings was also variable from one study to another, including histopathologic analy-sis (performed at surgery, biopsy, and autopsy), intraoperative observation (e.g., manual palpation or ultrasonogra-phy) and/or 6-months or 1-year follow-up. The rate of histological confirmation that is the gold standard particularly in the evaluation of false-positive and false-negative readings varied from < 10% to 95% (Truant et al., 2005). A non-standard method of image analysis, as well as some degree of inequivalence in FDG-PET and computed tomography (CT) performance, may have led to a misjudgement of their relative diagnostic performance, as reflected by high rates of FDG-PET/CT discordances (range, 10–31%). FDG-PET was performed prospectively and the interpretation of the FDG-PET images was generally made with a priori knowledge of results of conventional diagnostic procedures. In contrast, CT was reviewed retrospectively and performed at various institutions, resulting in its sensitivity and specificity rates being among the worst, which were reported in general literature regarding colorectal liver metastases. In the two meta-analyses performed in the beginning of the use of FDG-PET, only few studies fulfilled the inclusion criteria and the guidelines established by the authors, reflecting the limitations of published reports (Huebner et al., 2000; Kinkel et al., 2002). Over time, however, studies on FDG-PET have focused on more definite settings and have included more systematically histological verifications of FDG-PET findings, resulting in a better assessment of FDG-PET accuracy and impact. In this chapter, the yield of FDG-PET in colorectal liver metastases will be preferentially analyzed through these latter studies.

Keywords

Liver Metastasis Standardize Uptake Value Hepatic Resection Hepatic Metastasis Colorectal Liver Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Akhurst, T., Kates, T. J., Mazumdar, M., Yeung, H., Riedel, E. R., Burt, B. M., Blumgart, L., Jarnagin, W., Larson, S. M., and Fong, Y. 2005. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metas-tases. J. Clin. Oncol. 23: 8713–8716.PubMedCrossRefGoogle Scholar
  2. Anderson, G. S., Brinkmann, F., Soulen, M. C., Alavi, A., and Zhuang, H. 2003. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin. Nucl. Med. 28: 192–197.PubMedCrossRefGoogle Scholar
  3. Bipat, S., van Leeuwen, M. S., Comans, E. F., Pijl, M. E., Bossuyt, P. M., Zwinderman, A. H., and Stoker, J. 2005. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis meta-analysis. Radiology 237: 123–131.PubMedCrossRefGoogle Scholar
  4. Dimitrakopoulou-Strauss, A., Strauss, L. G., and Rudi, J. 2003. PET-FDG as predictor of therapy response in patients with colorectal carcinoma. Q. J. Nucl. Med. 47: 8–13.PubMedGoogle Scholar
  5. Even-Sapir, E., Parag, Y., Lerman, H., Gutman, M., Levine, C., Rabau, M., Figer, A., and Metser, U. 2004. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 232: 815–822.PubMedCrossRefGoogle Scholar
  6. Fernandez, F. G., Drebin, J. A., Linehan, D. C., Dehdashti, F., Siegel, B. A., and Strasberg, S. M. 2004. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann. Surg. 240: 438–447; discussion 447–450.PubMedCrossRefGoogle Scholar
  7. Findlay, M., Young, H., Cunningham, D., Iveson, A., Cronin, B., Hickish, T., Pratt, B., Husband, J., Flower, M., and Ott, R. 1996. Noninvasive monitoring of tumor metabolism using fluorode-oxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J. Clin. Oncol. 14: 700–708.PubMedGoogle Scholar
  8. Flamen, P., Stroobants, S., Van Cutsem, E., Dupont, P., Bormans, G., De Vadder, N., Penninckx, F., Van Hoe, L., and Mortelmans, L. 1999. Additional value of whole-body positron emission tomography with fluorine-18–2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J. Clin. Oncol. 17: 894–901.PubMedGoogle Scholar
  9. Flanagan, F. L., Dehdashti, F., Ogunbiyi, O. A., Kodner, I. J., and Siegel, B. A. 1998. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann. Surg. 227: 319–323.PubMedCrossRefGoogle Scholar
  10. Fong, Y., Saldinger, P. F., Akhurst, T., Macapinlac, H., Yeung, H., Finn, R. D., Cohen, A., Kemeny, N., Blumgart, L. H., and Larson, S. M. 1999. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am. J. Surg. 178: 282–287.PubMedCrossRefGoogle Scholar
  11. Goshen, E., Davidson, T., Zwas, S. T., and Aderka, D. 2006. PET/CT in the Evaluation of Response to Treatment of Liver Metastases from Colorectal Cancer with Bevacizumab and Irinotecan. Technol. Cancer. Res. Treat. 5: 37–44.PubMedGoogle Scholar
  12. Huebner, R. H., Park, K. C., Shepherd, J. E., Schwimmer, J., Czernin, J., Phelps, M. E., and Gambhir, S. S. 2000. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J. Nucl. Med. 41: 1177–1189.PubMedGoogle Scholar
  13. Kinkel, K., Lu, Y., Both, M., Warren, R. S., and Thoeni, R. F. 2002. Detection of hepatic metas-tases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 224: 748–756.PubMedCrossRefGoogle Scholar
  14. Lai, D. T., Fulham, M., Stephen, M. S., Chu, K. M., Solomon, M., Thompson, J. F., Sheldon, D. M., and Storey, D. W. 1996. The role of whole-body positron emission tomography with [18F]fluoro-deoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch. Surg. 131: 703–707.PubMedGoogle Scholar
  15. Langenhoff, B. S., Oyen, W. J., Jager, G. J., Strijk, S. P., Wobbes, T., Corstens, F. H., and Ruers, T. J. 2002. Efficacy of fluorine-18-deoxyglu-cose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J. Clin. Oncol. 20: 4453–4458.PubMedCrossRefGoogle Scholar
  16. Libutti, S. K., Alexander, H. R., Jr., Choyke, P., Bartlett, D. L., Bacharach, S. L., Whatley, M., Jousse, F., Eckelman, W. C., Kranda, K., Neumann, R. D., and Carrasquillo, J. A. 2001. A prospective study of 2-[18F] fluoro-2-de-oxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann. Surg. Oncol. 8: 779–786.PubMedCrossRefGoogle Scholar
  17. Moore, H. G., Akhurst, T., Larson, S. M., Minsky, B. D., Mazumdar, M., and Guillem, J. G. 2003. A case-controlled study of 18-fluorodeoxyglu-cose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J. Am. Coll. Surg. 197: 22–28.PubMedCrossRefGoogle Scholar
  18. Peeters, C. F., de Geus, L. F., Westphal, J. R., de Waal, R. M., Ruiter, D. J., Wobbes, T., Oyen, W. J., and Ruers, T. J. 2005. Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. Surgery 137: 246–249.PubMedCrossRefGoogle Scholar
  19. Rohren, E. M., Paulson, E. K., Hagge, R., Wong, T. Z., Killius, J., Clavien, P. A., and Nelson, R. C. 2002. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin. Nucl. Med. 27: 550–555.PubMedCrossRefGoogle Scholar
  20. Ruers, T. J., Langenhoff, B. S., Neeleman, N., Jager, G. J., Strijk, S., Wobbes, T., Corstens, F. H., and Oyen, W. J. 2002. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study. J. Clin. Oncol. 20: 388–395.PubMedCrossRefGoogle Scholar
  21. Schussler-Fiorenza, C. M., Mahvi, D. M., Niederhuber, J., Rikkers, L. F., and Weber, S. M. 2004. Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. J. Gastrointest. Surg. 8: 150–157; discussion 157–158.PubMedCrossRefGoogle Scholar
  22. Selzner, M., Hany, T. F., Wildbrett, P., McCormack, L., Kadry, Z., and Clavien, P. A. 2004. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann. Surg. 240: 1027–1034; discussion 1035–1036.PubMedCrossRefGoogle Scholar
  23. Spaepen, K., Stroobants, S., Dupont, P., Bormans, G., Balzarini, J., Verhoef, G., Mortelmans, L., Vandenberghe, P., and De Wolf-Peeters, C. 2003. [(18)F]FDG PET monitoring of tumour response to chemotherapy: does [(18)F]FDG uptake correlate with the viable tumour cell fraction? Eur. J. Nucl. Med. Mol. Imaging 30: 682–688.PubMedGoogle Scholar
  24. Strasberg, S. M., Dehdashti, F., Siegel, B. A., Drebin, J. A., and Linehan, D. 2001. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann. Surg. 233: 293–299.PubMedCrossRefGoogle Scholar
  25. Tanaka, T., Kawai, Y., Kanai, M., Taki, Y., Nakamoto, Y., and Takabayashi, A. 2002. Usefulness of FDG-positron emission tomography in diagnosing peritoneal recurrence of color-ectal cancer. Am. J. Surg. 184: 433–436.PubMedCrossRefGoogle Scholar
  26. Topal, B., Flamen, P., Aerts, R., D'Hoore, A., Filez, L., Van Cutsem, E., Mortelmans, L., and Penninckx, F. 2001. Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. Eur. J. Surg. Oncol. 27: 175–179.PubMedCrossRefGoogle Scholar
  27. Truant, S., Huglo, D., Hebbar, M., Ernst, O., Steinling, M., and Pruvot, F. R. 2005. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br. J. Surg. 92: 362–369.PubMedCrossRefGoogle Scholar
  28. Veit, P., Antoch, G., Stergar, H., Bockisch, A., Forsting, M., and Kuehl, H. 2006. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur. Radiol. 16: 80–87.PubMedCrossRefGoogle Scholar
  29. Vitola, J. V., Delbeke, D., Meranze, S. G., Mazer, M. J., and Pinson, C. W. 1996a. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization. Cancer 78: 2216–2222.CrossRefGoogle Scholar
  30. Vitola, J. V., Delbeke, D., Sandler, M. P., Campbell, M. G., Powers, T. A., Wright, J. K., Chapman, W. C., and Pinson, C. W. 1996b. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am. J. Surg. 171: 21–26.CrossRefGoogle Scholar
  31. Whiteford, M. H., Whiteford, H. M., Yee, L. F., Ogunbiyi, O. A., Dehdashti, F., Siegel, B. A., Birnbaum, E. H., Fleshman, J. W., Kodner, I. J., and Read, T. E. 2000. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis. Colon Rectum 43: 759–767; discussion 767–770.PubMedCrossRefGoogle Scholar
  32. Wong, C. Y., Salem, R., Qing, F., Wong, K. T., Barker, D., Gates, V., Lewandowski, R., Hill, E. A., Dworkin, H. J., and Nagle, C. 2004. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J. Nucl. Med. 45: 1892–1897.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2009

Authors and Affiliations

  • Stéphanie Truant
    • 1
  • Damien Huglo
    • 1
  • François-René Pruvot
    • 1
  1. 1.Service de Chirurgie Digestive et TransplantationHôpital HuriezLille CedexFrance

Personalised recommendations